Copyright
©The Author(s) 2025.
World J Virol. Mar 25, 2025; 14(1): 100489
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100489
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100489
Vaccine technology platforms | Intervention/treatment | ClinicalTrials.gov ID | Phase | Status | Sponsor |
Virus-like particle vaccine | Biological: VRC-CHKVLP059-00-VP | NCT01489358 | 1 | Completed | NIAID |
Biological: PXVX0317 | NCT03992872 | 2 | Completed | Bavarian Nordic | |
Biological: CHIKV VLP/adjuvant | NCT05072080 | 3 | Completed | Bavarian Nordic | |
Biological: VRC-CHKVLP059-00-VP | NCT02562482 | 2 | Completed | NIAID | |
Viral vectored vaccine | Biological: MV-CHIK/ Biological: MMR-vaccine | NCT03101111 | 2 | Completed | Themis Bioscience GmbH |
Biological: ChAdOx1 Chik | NCT04440774 | 1 | Completed | University of Oxford | |
Live attenuated vaccine | Biological: VLA1553 | NCT04650399 | 3 | Completed | Butantan Institute |
Biological: VLA1553 | NCT03382964 | 1 | Completed | Valneva Austria GmbH | |
Biological: V184 | NCT03807843 | 2 | Completed | Themis Bioscience GmbH | |
Inactivated whole virion vaccine | Biological: BBV87 | NCT04566484 | 3 | Completed | International Vaccine Institute |
- Citation: Cenci Dietrich V, Costa JMC, Oliveira MMGL, Aguiar CEO, Silva LGO, Luz MS, Lemos FFB, de Melo FF. Pathogenesis and clinical management of arboviral diseases. World J Virol 2025; 14(1): 100489
- URL: https://www.wjgnet.com/2220-3249/full/v14/i1/100489.htm
- DOI: https://dx.doi.org/10.5501/wjv.v14.i1.100489